Faculty

Geoffrey B. Johnson, M.D., Ph.D.

Clinical Studies

A Phase 3, Multicenter, Open Label Study To Confirm The Diagnostic Potential Of Intravenously Administered [15-O]-H2O To Identify Coronary Artery Disease During Pharmacological Stress And Resting Conditions Using PET Imaging Rochester, Minn.
The purpose of this study is to determine the sensitivity and specificity of the 15O-H2O PET myocardial perfusion imaging (MPI) study to detect coronary artery disease (CAD) using the truth-standard of invasive coronary angiogram (ICA) with fractional flow reserve (FFR) or coronary computed tomography angiogram (CCTA).
Phase 1b/2 Open-label Trial Of 225Ac-DOTATATE (RYZ101) In Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced And Unresectable Or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) And Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1) Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
The purpose of this study is to determine the recommended phase 2 dose (RP2D), the optimal treatment regimen and to evaluate preliminary efficacy of RYZ101 in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally advanced and unresectable or metastatic breast cancer.

68Ga-PSMA-11 PET/CT For Screening Prior To 177Lu-PSMA-617 Therapy Rochester, Minn.
The purpose of this study is the diagnostic 68Ga-PSMA-11 PET/CT imaging for screening prior to consideration of 177Lu-PSMA-617 therapy.
A Phase 1, First-in-human Clinical Trial Of 203PbVMT01/212PbVMT01 Using A Forward Dosimetric Planning Technique To Treat Refractory Or Metastatic Melanoma Rochester, Minn.
The purpose of this study is to determine safety and measure biodistribution of two imaging agents in patients with refractory or metastatic melanoma. This study will use [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) imaging.
A Phase I/IIa Theranostic Study Of 64Cu-SAR-bisPSMA And 67Cu-SAR-bisPSMA For Identification And Treatment Of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer Rochester, Minn. The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Expanded Access Ga68 PSMA PET Imaging Rochester, Minn.
The primary objective of this study is to provide access to [Ga-68] PSMA-11 imaging (PET/CT or PET/MR) for patients diagnosed with untreated high-risk prostate cancer or biochemically recurrent prostate cancer.